Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Studying the Microenvironment And Related Targets in Non-Hodgkin's Lymphoma

Descrizione del progetto

Nuovi indizi sul microambiente tumorale delle neoplasie linfoidi

Il microambiente tumorale è cruciale nell’evoluzione del cancro e nella risposta alla terapia, in particolare per quanto riguarda l’immunoterapia antitumorale. Finanziato dal programma di azioni Marie Skłodowska-Curie, il progetto SMART-NHL si concentra sulla leucemia linfocitica cronica e sul linfoma a cellule mantellari, due neoplasie linfoidi dotate di similitudini relative. I ricercatori del progetto mirano a scoprire l’interazione tra il microambiente tumorale e le cellule neoplastiche in queste due patologie avvalendosi di analisi a singole cellule e sistemi di coltura 3D per studiare le interazioni cellulari e identificare gli attori molecolari che influenzano la progressione del cancro e la resistenza alle terapie. I risultati di SMART-NHL potrebbero portare a nuovi modelli di stratificazione del rischio dei pazienti, nonché a obiettivi terapeutici inediti.

Obiettivo

The tumor microenvironment (TME) plays an essential role in tumor evolution and response to therapy. Understanding the complex network comprising tumor and immune cells is critical for the success of cancer immunotherapy. CLL and MCL are two non-Hodgkin’s lymphomas characterized by accumulating CD5+ small and mature B lymphocytes in peripheral blood, bone marrow, lymph nodes, and extranodal sites. Despite having distinct basic pathogenic mechanisms, they share the cell of origin and molecular alterations, clinical features, and epidemiological characteristics. However, the influence of the crosstalk between tumor cells and the TME on the disease progression and treatment resistance remains poorly understood, hindering the development of novel therapeutic possibilities.
This study aims to uncover the intricate interplay between the TME and neoplastic cells in CLL and MCL and exploit its therapeutic use. To achieve this, I will use single-cell RNA sequencing and spatial transcriptomics to analyze the composition of non-tumoral cells in tumor-involved tissues and at different time points of the disease. Next, I will use correlative analyses to identify the molecular and cellular interactions between the tumor cell (epi)genomic configuration and the TME, determining tumor evolution and response to therapy. Finally, I will validate the identified drivers of disease evolution and treatment resistance and examine their potential as a target for treatment using a 3D LN-derived culture system. The findings have the potential to provide a solid basis for establishing new models of patient risk stratification and identify potential therapeutic opportunities targeting interactions between tumor cells and their microenvironment.
Conducting this project at the Molecular Pathology of Lymphoid Neoplasms group of Prof. Dr. Elias Campo will provide me an opportunity to acquire essential technical and soft skills vital for advancing my career in research.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2023-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Contributo netto dell'UE
€ 181 152,96
Indirizzo
CARRER ROSSELLO 149
08036 Barcelona
Spagna
Regione
Este Cataluña Barcelona
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato